Abstract
Background Understanding the genetics of liver disease has the potential to facilitate clinical risk stratification. We recently identified six genes and one lncRNA enriched for acquired somatic mutations in patients with NAFLD and alcohol-related liver disease. We hypothesised that germline variation in these genes would be associated with risk of liver disease development and contribute to prognostication.
Methods Genome-wide association study (GWAS) summary statistics were extracted from seven studies (>1.7 million participants) for variants near ACVR2A, ALB, CIDEB, FOXO1, GPAM, NEAT1 and TNRC6B for: aminotransferases, liver fat, HbA1c, diagnosis of NAFLD, ARLD, and cirrhosis. Findings were replicated using GWAS data from multiple independent cohorts. A phenome-wide association study was performed to examine for related metabolic traits, using both common and rare variants, including gene-burden testing.
Results There was no evidence of association between rare germline variants or SNPs near five genes (ACVR2A, ALB, CIDEB, FOXO1, and TNRC6B) and risk or severity of liver disease. Variants in GPAM were associated with liver fat (p=3.6×10-13), ALT (p=2.8×10-39), and serum lipid concentrations. Variants in NEAT1 demonstrated borderline significant associations with ALT (p=1.9×10-11) and HbA1c, but not with liver fat, as well as influencing waist-to-hip ratio, adjusted for BMI.
Conclusions Despite strong selective advantage to acquire somatic mutations at these loci, there was no evidence of an association between germline variation and markers of liver disease, except in GPAM. Polygenic risk scores based on germline variation alone will not capture prognostic data from genes affected by somatic mutations.
Competing Interest Statement
MH is a co-inventor on a patent detailing the finding of recurrent somatic mutations in chronic liver disease.
Funding Statement
JPM is supported by a Wellcome Trust fellowship (216329/Z/19/Z); MH is supported by a CRUK Advanced Clinician Scientist fellowship (C52489/A19924); CRUK-OHSU Project Award (C52489/A29681) and CRUK Accelerator award to the HUNTER consortium (C18873/A26813).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK BioBank Summary Stats: https://pan.ukbb.broadinstitute.org/ FinnGen: https://www.finngen.fi/en BioBank Japan: http://jenger.riken.jp/en/ Other GWAS Summary Statistics: https://www.ebi.ac.uk/gwas/downloads/summary-statistics Common Metabolic Disease Knowledge Portal: https://hugeamp.org/ MAGIC summary stats: https://magicinvestigators.org/downloads/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Authors’ declaration of personal interests: MH is a co-inventor on a patent detailing the finding of recurrent somatic mutations in chronic liver disease.
Funding: JPM is supported by a Wellcome Trust fellowship (216329/Z/19/Z); MH is supported by a CRUK Advanced Clinician Scientist fellowship (C52489/A19924); CRUK-OHSU Project Award (C52489/A29681) and CRUK Accelerator award to the HUNTER consortium (C18873/A26813).
Data Availability
All summary statistics are available in the article and supplementary data. Code used in analysis is available via https://doi.org/10.5281/zenodo.4656979.
